Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 4578-4578
Author(s):  
Mayer N. Fishman ◽  
Joseph I Clark ◽  
Ajjai Shivaram Alva ◽  
Brendan D. Curti ◽  
Neeraj Agarwal ◽  
...  
Keyword(s):  
Overall Survival ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Risk Category ◽  
High Dose ◽  
Clinical Risk ◽  
Metastatic Renal Cell Cancer

Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?

2011 ◽  
Vol 26 (3) ◽  
pp. 273-277 ◽  
Author(s):  
Robert O. Dillman ◽  
Neil M. Barth ◽  
Louis A. VanderMolen ◽  
Warren H. Fong ◽  
Khosrow K. Mahdavi ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
High Dose ◽  
Metastatic Renal Cell Cancer

Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer

2008 ◽  
Vol 31 (6) ◽  
pp. 569-576 ◽  
Author(s):  
Nicolas Acquavella ◽  
Harriet Kluger ◽  
John Rhee ◽  
Leonard Farber ◽  
Harold Tara ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
High Dose ◽  
Metastatic Renal Cell Cancer

Acute morphine intoxication during high-dose recombinant interleukin-2 treatment for metastatic renal cell cancer

1994 ◽  
Vol 30 (12) ◽  
pp. 1905-1907 ◽  
Author(s):  
R. Bortolussi ◽  
F. Fabiani ◽  
F. Savron ◽  
V. Testa ◽  
R. Lazzarini ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
High Dose ◽  
Metastatic Renal Cell Cancer ◽  
Recombinant Interleukin 2

Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Skin Reaction ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Cox Models ◽  
Metastatic Renal Cell Cancer ◽  
Hand Foot Skin Reaction

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.

Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study

1989 ◽  
Vol 16 ◽  
pp. 111-113 ◽  
Author(s):  
G. Stoter ◽  
S.D. Fosså ◽  
C. Rugarli ◽  
M. Symann ◽  
C. Jasmin ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Low Dose ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Metastatic Renal Cell Cancer

scholarly journals Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-α

1990 ◽  
Vol 1 (5) ◽  
pp. 377-378 ◽  
Author(s):  
J. Atzpodien ◽  
A. Körfer ◽  
P.A. Palmer ◽  
C.R. Franks ◽  
H. Poliwoda ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Interferon Α ◽  
Metastatic Renal Cell Cancer

Fluorouracil+interferon alfa+ interleukin-2 chemoimmunotherapy in metastatic renal cell cancer patients

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4682-4682
Author(s):  
O. Er ◽  
M. Ozkan ◽  
M. Altinbas ◽  
S. H. Coskun ◽  
B. Eser ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Interferon Alfa ◽  
Metastatic Renal Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document